Publications by authors named "Malini M Gandhi"
Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.
View Article and Find Full Text PDFArticle Synopsis
- Activating point mutations in the MET tyrosine kinase domain are identified as oncogenic drivers in various cancers, occurring in about 0.5% of cases, particularly in certain papillary renal cell carcinomas.
- Specific mutations at positions H1094, L1195, F1200, D1228, Y1230, and M1250 were labeled as oncogenic or likely oncogenic based on genetic profiling.
- Preclinical models and patient responses indicate that these mutations may enhance sensitivity to MET inhibitors, highlighting the potential for targeted precision treatments in oncology.
Background: Developing countries experience limited access to HCV laboratory tests for different reasons. Providing near to real-time HCV testing and results especially to at-risk populations including those in rural settings for timely initiation to treatment is key. Within a rural Myanmar setting, we compared HCV diagnostic detection and quantification of the GeneXpert, and Advanced Biological Laboratories UltraGene-HCV assays against the gold standard and reference method Roche real-time HCV in Myanmar.
View Article and Find Full Text PDFPurpose: rearrangements and activating point mutations represent targetable genomic alterations in advanced solid tumors. However, the frequency and clinicopathologic characteristics of wild-type amplification in cancer and its potential role as a targetable oncogenic driver are not well-characterized.
Methods: In two institutional cohorts of patients with solid cancers from the Dana-Farber Cancer Institute (DFCI) and Memorial Sloan Kettering Cancer Center (MSKCC) whose tumors underwent next-generation sequencing (NGS), the frequency and clinicopathologic features of wild-type amplification in the absence of rearrangements or activating mutations was assessed.
There is a need to identify predictive biomarkers to guide treatment strategies in stage III non-small cell lung cancer (NSCLCs). In this multi-institutional cohort of 197 patients with stage III NSCLC treated with concurrent chemoradiation (cCRT) and durvalumab consolidation, we identify that low tumor aneuploidy is independently associated with prolonged progression-free survival (HR 0.63; p=0.
View Article and Find Full Text PDFArticle Synopsis
- The study compared PCSK9 levels in individuals with co-existing HIV and hepatitis C (HIV/HCV) vs. those with HIV alone, finding that PCSK9 levels were higher in the HIV/HCV group but not significantly so (P = 0.06).
- Following direct-acting antiviral (DAA) therapy for HCV, PCSK9 levels significantly declined in the HIV/HCV group, reaching levels similar to the HIV alone group (P = 0.003 and P = 0.02).
- The drop in PCSK9 was associated with reductions in inflammatory markers, suggesting that elevated PCSK9 in HIV/HCV may be more related to inflammation rather than cholesterol levels.
Introduction: Although gene-level copy number alterations have been studied as a potential biomarker of immunotherapy efficacy in NSCLC, the impact of aneuploidy burden and chromosomal arm-level events on immune checkpoint inhibitor (ICI) efficacy in NSCLC is uncertain.
Methods: Patients who received programmed cell death protein 1 or programmed death-ligand 1 (PD-L1) inhibitor at two academic centers were included. Across all 22 chromosomes analyzed, an arm was considered altered if at least 70% of its territory was either gained or deleted.
Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine.
JGH Open
December 2022
Background And Aim: To demonstrate the use of a standard dose of ledipasvir (LDV) and sofosbuvir (SOF), with or without ribavirin, to treat hepatitis C and hepatitis C/HIV co-infection in Ukraine.
Methods: Eligible HCV viraemic adults from two clinics in Kyiv were treated with LDV/SOF with or without weight-based ribavirin for 12 weeks. Clinical assessments were performed at screening and at week 24, and as needed; treatment was dispensed every 4 weeks.
Access to hepatitis C virus (HCV) testing and treatment is limited in Myanmar. We assessed an integrated HIV and viral hepatitis testing and HCV treatment strategy. Sofosbuvir/velpatasvir (SOF/VEL) ± weight-based ribavirin for 12 weeks was provided at three treatment sites in Myanmar and sustained virologic response (SVR) assessed at 12 weeks after treatment.
View Article and Find Full Text PDFBackground And Aim: Direct-acting antivirals (DAAs) have increased hepatitis C virus (HCV) treatment opportunities for vulnerable HIV/HCV coinfected persons. The aim of this study was to identify the frequency of and potential barriers to DAA prescription in HIV/HCV patients during the first few years of DAA availability in the United States.
Methods: The AIDS Healthcare Foundation electronic medical record system was queried to identify all HCV viremic HIV-infected patients in care at AIDS Healthcare Foundation Healthcare centers in January 2015-August 2017 and compare characteristics by receipt of a DAA prescription.